Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Lucentis image

Lucentis not backed by NICE for new licence

November 24, 2011
Sales and Marketing Lucentis, NICE, Novartis, Ozurdex

NICE has not recommended Novartis’ eye disease drug Lucentis due to ‘gaps and uncertainties’ in the manufacturer’s submission. In draft …

News
Eylea picture

Lucentis rival gains US approval

November 22, 2011
Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche

A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …

News

Novartis workers stage flash strike over job cuts

November 21, 2011
Manufacturing and Production Novartis, Switzerland, job cuts

Workers at Novartis’ Nyon facility in Switzerland carried out a strike to protest the closure of the plant, but called …

News

Timothy Wright appointed as global head of development at Novartis Pharmaceuticals

November 9, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis

Novartis has appointed Dr Timothy Wright as the new global head of development of its pharmaceuticals business, effective immediately.  Dr …

Appointment
peter_maag

Carsten Schroeder appointed interim president of Novartis Diagnostics

October 31, 2011
Sales and Marketing Novartis

Schroeder was previously vice president of Novartis Diagnostics for commercial operations in Europe, the Middle East and Africa. He will …

Appointment
Swiss protest image

Novartis job cuts protest

October 31, 2011
Manufacturing and Production, Sales and Marketing Novartis, job cuts, manufacturing and production

Protesters have been demonstrating outside the home of Novartis chairman Daniel Vasella and in the streets of Basel, Switzerland, in …

News

Novartis loses global development head to Gates Foundation

September 14, 2011
Research and Development Bill and Melinda Gates Foundation, Novartis, appointment

Novartis’ global head of development Trevor Mundel is to leave the company and take a senior position at The Bill …

News
Novartis

Everolimus approved to treat rare tumour disease

September 8, 2011
Sales and Marketing Novartis, SEGA, Votubia, everolimus

Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …

News
Novartis Afinitor

Afinitor expands European licence

September 5, 2011
Sales and Marketing Afinitor, Novartis, Pancreatic cancer

Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …

News
Gilenya

Gilenya rejected by NICE

August 5, 2011
Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya

NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …

News

Afinitor poised to realise blockbuster ambitions?

July 25, 2011
Sales and Marketing Afinitor, Cancer, Novartis

Novartis’ Afinitor may be set to make good on its blockbuster promise after receiving European backing for its second licence …

News
Novartis

Novartis posts double-digit sales and profit growth

July 19, 2011
Sales and Marketing Novartis

Novartis had a strong second quarter of the year, with both sales and profit up on the same period in …

News

NICE decides laser treatment better than Lucentis

July 18, 2011
Sales and Marketing Lucentis, NICE, Novartis

Novartis says it is “disappointed” with health watchdog NICE’s decision not to recommend Lucentis for the treatment of eye problems …

News

Novartis’ Votubia reduces benign brain tumours in SEGA patients

July 11, 2011
Research and Development Novartis, SEGA, Votubia, everolimus

Novartis’ novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus …

News
Novartis Afinitor (everolimus)

Afinitor stops tumour growth in advanced breast cancer

July 5, 2011
Manufacturing and Production, Research and Development Afinitor, Novartis, Votubia, advanced breast cancer

Novartis’ Afinitor has impressed in a late-stage trial by increasing survival in women with advanced breast cancer. The phase III …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026